Clinical trials: Hemostatic Disorders
Multiple Myeloma, Relapsed and Refractory Multiple Myeloma
A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma
This study is designed to evaluate the tolerability and safety of HG146 capsule in patients with multiple myeloma.
- Trial name
- NCT03710915
- Testing
- HG146
- Where
- China
- Volunteers
- 3 people
- Sponsor
- HitGen Inc.
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT04988555
- Testing
- Enzomenib, azoles, Venetoclax
- Where
- 104 sites in United States, Belgium and 10 more
- Volunteers
- 606 people
- Sponsor
- Sumitomo Pharma America, Inc.
Lymphoma, Multiple Myeloma
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).
- Trial name
- ELOQUENT - 2 (NCT01239797)
- Testing
- Lenalidomide, Dexamethasone, Dexamethasone (Oral)
- Where
- 216 sites in United States, Australia and 21 more
- Volunteers
- 646 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
This is a multicenter, open-label, Phase 1b study to determine the recommended dose and regimen of durvalumab either as monotherapy or in combination with POM with or without low dose dex in subjects with RRMM.
- Trial name
- NCT02616640
- Testing
- Durvalumab, Pomalidomide, Dexamethasone
- Where
- 22 sites in United States, Canada and 5 more
- Volunteers
- 114 people
- Sponsor
- Celgene
Relapsed/Refractory Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each combination…
- Trial name
- NCT06655818
- Testing
- Belantamab Mafodotin, Dostarlimab
- Where
- 3 sites in France, South Korea
- Volunteers
- 4 people
- Sponsor
- GlaxoSmithKline
Blood Loss, Surgical, Coagulation Disorder
Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
The goal of this clinical trial is to learn if reltodecacog alfa (VMX-C001) works to to allow blood clotting control in participants who take FXa Direct Oral Anticoagulants (DOACs) during surgery or other invasive procedures that…
- Trial name
- EQUILIBRIX-S (NCT07288489)
- Testing
- Reltodecacog alfa, Usual Pharmacological Care
- Where
- 77 sites in United States, Australia and 16 more
- Volunteers
- 800 people
- Sponsor
- VarmX B.V.
Multiple Myeloma
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
This study tests the safety of a drug called SGN-CD352A, to find out what its side effects are. SGN-CD352A will be given every 4 weeks to a small group of patients with multiple myeloma.
- Trial name
- NCT02954796
- Testing
- SGN-CD352A
- Where
- 11 sites in United States
- Volunteers
- 27 people
- Sponsor
- Seagen Inc.
Multiple Myeloma
Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine the efficacy of lenalidomide plus low-dose dexamethasone in Chinese subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT01593410
- Testing
- Lenalidomide, Dexamethasone
- Where
- 13 sites in China
- Volunteers
- 194 people
- Sponsor
- Celgene
Hemostasis, Oral Contraceptive
A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women
This study is being conducted to evaluate the impact of DR-102, a 28-day oral contraceptive compared to a standard 28-day oral contraceptive regimen on hemostatic parameters in healthy women.
- Trial name
- NCT01388491
- Testing
- desogestrel/ethinyl estradiol and ethinyl estradiol, desogestrel/ethinyl estradiol
- Where
- 27 sites in Germany, Israel and 2 more
- Volunteers
- 293 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Cerebral Cavernous Malformation
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in participants with symptomatic…
- Trial name
- SYCAMORE (NCT05085561)
- Testing
- REC-994
- Where
- 15 sites in United States
- Volunteers
- 62 people
- Sponsor
- Recursion Pharmaceuticals Inc.
Multiple Myeloma
A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)
This is a randomized, blinded, placebo-controlled, multicenter, Phase II study designed to provide a preliminary assessment of the safety and efficacy of combining bevacizumab with bortezomib in patients with relapsed or…
- Trial name
- AMBER (NCT00473590)
- Testing
- Bevacizumab, Bortezomib
- Volunteers
- 102 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
The purpose of this study is to evaluate safety and effectiveness of CNTO 328 (siltuximab) when it is administered together with velcade-melphalan-prednisone (VMP) in comparison with VMP alone in participants with multiple…
- Trial name
- NCT00911859
- Testing
- Siltuximab11 mg/kg, Siltuximab 8.3 mg/kg or 11 mg/kg, Velcade (bortezomib)
- Where
- 37 sites in United States, Australia and 9 more
- Volunteers
- 118 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
The primary purpose of the study is to determine the safety and efficacy and to generate PK and biomarker data for the combination of Pomalidomide and low-dose Dexamethasone in patients with relapsed or refractory multiple…
- Trial name
- NCT02045017
- Testing
- Pomalidomide and Dexamethasone
- Where
- 22 sites in Austria, France and 6 more
- Volunteers
- 81 people
- Sponsor
- Celgene
Multiple Myeloma
A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma
Oncocort Dexamethasone sodium phosphate encapsulated in so-called 'long-circulating' PEGylated liposomes is in development with the prospect of providing enhanced and prolonged lesion uptake of dexamethasone and therefore…
- Trial name
- AMETHYST (NCT03033316)
- Testing
- Dexamethasone
- Volunteers
- 7 people
- Sponsor
- Enceladus Pharmaceuticals BV
Multiple Myeloma
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or…
- Trial name
- MajesTEC-9 (NCT05572515)
- Testing
- Teclistamab, Pomalidomide, Bortezomib
- Where
- 211 sites in United States, Australia and 22 more
- Volunteers
- 614 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells.
- Trial name
- CARTIFAN-1 (NCT03758417)
- Testing
- LCAR-B38M CAR-T Cell
- Where
- 11 sites in China
- Volunteers
- 123 people
- Sponsor
- Nanjing Legend Biotech Co.
Relapsed and Refractory Multiple Myeloma
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
This study will determine the safety profile, tolerability, and maximum tolerated dose (MTD) and disease response of Ixazomib administered orally in participants with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT00932698
- Testing
- Ixazomib
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Relapsed/Refractory Multiple Myeloma (RRMM)
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
This study is researching whether the use of tocilizumab before the first dose of linvoseltamab will decrease the risk of Cytokine Release Syndrome (CRS) in participants who have Relapsed or Refractory Multiple Myeloma (RRMM) who…
- Trial name
- POPLIN (NCT07609940)
- Testing
- Linvoseltamab, Tocilizumab
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma
This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.
- Trial name
- NCT00086216
- Testing
- Atiprimod
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Callisto Pharmaceuticals
Multiple Myeloma
A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
This study will evaluate melflufen in combination with dexamethasone in adult patients with relapsed or refractory multiple myeloma in whose disease is refractory to pomalidomide and/or an anti-CD38 monoclonal antibody.
- Trial name
- HORIZON (NCT02963493)
- Testing
- Melphalan flufenamide (Melflufen), Dexamethasone
- Where
- 20 sites in United States, France and 2 more
- Volunteers
- 157 people
- Sponsor
- Oncopeptides AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.